Episode Details
Back to Episodes
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Season 1
Published 2 years, 5 months ago
Description
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here